Document is current
Any future updates will be listed below
-
Authors
Kobayashi, Hiroki https://orcid.org/0000-0002-3785-2317
Komizo, Yuta
Watanabe, Nanami
Miyata, Yu
Ohnuma, Yoshiya
Kamimura-Aoyagi, Yasushige
Yuki, Kanako
Hayashi, Yoshihiro
Yoshida, Minoru https://orcid.org/0000-0002-4376-5674
Harada, Yuka https://orcid.org/0000-0002-4550-3176
Harada, Hironori https://orcid.org/0000-0001-9401-5470
- License Information
-
More Information
Article History
Received: 30 January 2025
Revised: 29 June 2025
Accepted: 1 August 2025
First Online: 14 August 2025
Competing interests
: HK and HH filed a patent for applications of therapeutic compounds for hematological disorders, including those described in this study. Patent names: “Therapeutic compounds for hematological disorders.” Patent applicant: Tokyo University of Pharmacy and Life Sciences. Name of inventors: HK and HH. Patent number: Japanese Patent Application No. 2024-228529. Patent status: pending. Specific aspect of the manuscript covered in the patent application: The patent application covers the application of crizotinib to increase platelet counts in MDS patients. HK received a research grant from Nippon Shinyaku Co., Ltd. HH has received advisory board fees from Novartis. The other authors have no conflicts of interest to declare.
